Cellosaurus SK-N-BE(1) (CVCL_9898)

Cell line name SK-N-BE(1)
Synonyms SKNBE(1); SKNBE-1
Accession CVCL_9898
Resource Identification Initiative To cite this cell line use: SK-N-BE(1) (RRID:CVCL_9898)
Comments From: Memorial Sloan-Kettering Cancer Center; New York; USA.
Characteristics: Neuroblastic type (N-type) (PubMed=15720811).
Doubling time: 96 hours (COG).
Disease Neuroblastoma (NCIt: C3270)
Derived from metastatic site: Bone marrow.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_0528 ! SK-N-BE(2)
Sex of cell Male
Age at sampling 1Y10M
Category Cancer cell line
STR profile Source(s): COG

Markers:
AmelogeninX,Y
CSF1PO10
D13S31711
D16S5399,11
D18S5114,16
D19S43312,13
D21S1130,32.2
D2S133817,23
D3S135819
D5S81812
D7S8209,10
D8S117913,14
FGA22,25
TH016
TPOX8,11
vWA18
Web pages http://www.cogcell.org/dl/NB_Data_Sheets/SK-N-BE1_Cell_Line_Data_Sheet_COGcell_org.pdf
Publications

PubMed=29704
Biedler J.L., Roffler-Tarlov S., Schachner M., Freedman L.S.
Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones.
Cancer Res. 38:3751-3757(1978)

PubMed=2535691
Ciccarone V., Spengler B.A., Meyers M.B., Biedler J.L., Ross R.A.
Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages.
Cancer Res. 49:219-225(1989)

DOI=10.1007/0-306-46872-7_2
Thiele C.J.
Neuroblastoma.
(In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999)

PubMed=15720811; DOI=10.1593/neo.04310
Walton J.D., Kattan D.R., Thomas S.K., Spengler B.A., Guo H.-F., Biedler J.L., Cheung N.-K.V., Ross R.A.
Characteristics of stem cells from human neuroblastoma cell lines and in tumors.
Neoplasia 6:838-845(2004)

PubMed=24792489; DOI=10.1007/s11060-014-1456-8
Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P., Lau L.M.S.
Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
J. Neurooncol. 119:17-26(2014)